From Boom to Gloom: SPAC Frenzy Fizzles in Asia after US Falters
The SPAC bandwagon that rolled out of the U.S. has gone off the rails in Asia. Some listed SPACs have been liquidated, and the volume of SPAC applications in Singapore…
Viva Biotech Dispenses Bitter Pill of Slowing Growth, Asset Devaluation
The contract drug services provider lost roughly 100 million yuan in the first half of this year, as its revenue growth underperformed its peers Key Takeaways: Viva Biotech’s eked out…
RELATED ARTICLES
-
Synagistics holds potential to enliven moribund Hong Kong SPAC market
7841.HK -
ZG Group and Aquila aim to score Hong Kong’s first SPAC merger success
7836.HK
-
Hong Kong’s lukewarm IPO market may be about to heat up
0388.HK
-
Hong Kong typhoon trading halts sail into the sunset
0388.HK
-
Chinese securities regulator puts lid on Hong Kong IPO tea party
2150.HK 2555.HK
- China reaffirms support for offshore IPOs, but new listings likely to remain small
